A few of you have expressed interest in the behind-the-scenes process of launching the global asset management business Aaron and I are establishing to provide a mechanism to take on outside funds alongside our own; a natural extension of what we’ve been doing for so many years privately…
Johnson & Johnson is one of the most successful businesses in global history but its rise to preeminence resulted in an ugly family battle that left a wake of victims behind the misbehavior of two deeply flawed brothers.
After writing the post on investing in the oil majors (if you can call it that – I’m genuinely sorry about reaching almost 6,100 words as I didn’t plan on making it so lengthy) – explaining how you’re being paid to absorb volatility over very long periods of time that other people don’t want on their…
I’ve received a significant number of requests over the past few months asking that I discuss what is happening with oil, natural gas, pipeline, and refining companies; to explain how I look at the situation and the sorts of things Aaron and I discuss when we’re allocating our own capital or the capital of those who have entrusted their assets to us. It’s a big topic with a lot of niche considerations but I want to take some time today to address the oil majors; the handful of mega-capitalization behemoths such as ExxonMobil, Chevron, Royal Dutch Shell, Total, ConocoPhillips / Phillips 66, and BP.
My brother’s white coat ceremony for medical school was this past Saturday! We went to cheer him on as he was assigned to his docent, with the internal medicine experience up first. (Though he’s part of the class of 2019, I think he’s graduating in 2018 because of however his particular academic experience and credit history happened to coalesce. I’m not entirely clear on how the mechanics work. Whatever it is, it won’t be long before we’re calling him “Dr. Kennon”.)
After so many years of investing, interacting with people, and writing about stocks, mutual funds, index funds, and portfolio management, I have five theories that help explain investor behavior.
I spent all day working on the new business we’re launching, trying to figure out the pricing structure I want to use and the cut-offs I want to enforce before we get ready to file the regulatory paperwork, while Aaron oversaw the re-platforming of the sporting goods company. We came together around dinner time to…
On a recent late-night restocking run to the store, Aaron and I were walking down an aisle when we suddenly spotted something that, outside of a handful of enclaves, has been missing in action or relegated to back corners for decades: A product called Noxzema. For almost three-quarters of a century, the stuff was ubiquitous, found in nearly every home and an absolute must-have on any shopping trip taken by nearly any American family. The business story behind the Noxema fortune is a fascinating one.
I’ve publicly written many times about my extreme discomfort with the direction of certain technological innovations; how, left unchecked without explicit guarantees of privacy, they could lead to what one Supreme Court justice described as a turn-key totalitarian state. In the wrong hands, there would be nowhere to run, no place to hide. It’s not…
I’ve been thinking about the story that has captivated the country over the past two days – how, if various news reports are to be believed, Dr. Walter J. Palmer of Eden Prairie, Minnesota, owner of a practice called River Bluff Dental in Bloomington, Minnesota, and two of his guides poached the beloved Cecil the Lion from a national park in Zimbabwe, luring him from the sanctuary where he was protected, injuring him with an arrow before tracking him for two days, shooting him, beheading him, skinning him, and leaving the body behind with plans to mount the trophy in his office.